US Patent 5,591,762 Scope, Claim Structure, and US Patent Landscape
US Patent 5,591,762 claims a class of benzimidazole-containing substituted biphenyl carboxylic acids and tetrazolyl biphenyl analogs, with a defined, heavily substituted benzimidazole core and controlled substituent positions on the biphenyl framework. The patent’s effective “scope” is driven by (i) the generic structural formula limitations on R1 to R4, (ii) inclusion of specific enumerated species in claims 4 to 6, and (iii) downstream coverage via pharmaceutical composition and method of treating hypertension claims.
What is the claim architecture in US 5,591,762?
The patent includes a typical sequence of compound, subset, species, and downstream use claims.
Claim 1 (core Markush-style genus)
Claim 1 covers “a compound of formula I” defined by substituent variables R1, R2, R3, R4, and the stereochemical/positional logic encoded in the formula.
Key variable constraints:
-
R1 (4-position) is one of:
- C1-4-alkyl
- C3-7-cycloalkyl
- trifluoromethyl
-
R2 is:
- benzimidazol-2-yl
- optionally substituted at the 1-position by:
- C1-6-alkyl or C3-7-cycloalkyl
-
Additional substitution option on the phenyl nucleus (benzimidazole benzene ring):
- fluorine, or
- methyl, or
- trifluoromethyl
-
R3 is one of:
- C1-5-alkyl or cyclopropyl
-
R4 is one of:
- 1H-tetrazolyl
- or Ra O--CO-- group
-
Ra is:
- hydrogen
- or straight-chained or branched C1-4-alkyl
-
The claim also covers pharmaceutically acceptable salts of the covered compounds.
Claim 2 (position-dependent narrowing on R2)
Claim 2 limits Claim 1 by requiring:
- R2 is in the 6-position (within the formula framework), or a pharmaceutically acceptable salt.
Claim 3 (further fixed substituent set)
Claim 3 narrows the genus to specific choices:
- R1 = methyl
- R2 = benzimidazol-2-yl, optionally substituted at 1-position by C1-3-alkyl
- Benzo ring substituted by:
- fluorine allowed on one of the benzimidazole phenyl nuclei
- R3 = C1-5-alkyl
- R4 = carboxy or 1H-tetrazolyl
- plus salts
Claim 4 (explicit enumerated species set)
Claim 4 enumerates six concrete compounds (a mix of carboxylic acid and tetrazolyl variants), each defined as a fully specified substituted biphenyl structure with the benzimidazole substituent architecture.
Claims 5 and 6 (subset of enumerated species)
Claim 7 (composition)
- Covers a pharmaceutical composition comprising a therapeutically effective amount of a compound of claims 1, 2, 3, 4, 5, or 6.
Claim 8 (method of treating hypertension)
- Covers a method for treating hypertension by administering an antihypertensive amount of a compound of claims 1, 2, 3, 4, 5, or 6.
Practical implication: The patent’s enforceable scope stretches from a broad structural genus (Claim 1) to narrower positional and substituent variants (Claims 2 and 3), then to a set of explicit named compounds (Claim 4) and two single-species anchors (Claims 5 and 6). The composition and method claims ride on the same compound set.
What does the substituent logic mean for real-world coverage?
R1 on the “4-position”
Claim 1 allows R1 = C1-4 alkyl, C3-7 cycloalkyl, or trifluoromethyl. This is a broad peripheral flexibility on the aromatic core. It supports designing around single-point modifications at the R1 locus, but the modified compound must still preserve the benzimidazole and R4 patterns.
R2’s dual substitution pattern (1-position and benzene ring)
R2 is constrained to benzimidazol-2-yl with optional substitution at:
- 1-position (alkyl or cycloalkyl)
- benzene ring (fluorine, methyl, or trifluoromethyl)
This is where most “design-around” pressure lands. If a competitor changes R2 to a different heteroaromatic orientation or changes the benzene ring substituent class beyond F/methyl/CF3, it will fall outside the Claim 1 genus.
R3 (methylene-adjacent substituent)
R3 is limited to C1-5 alkyl or cyclopropyl. Larger alkyls or other ring systems outside cyclopropyl are not included.
R4 (tetrazolyl vs. carboxylate-like Ra O--CO--)
R4 includes:
- 1H-tetrazolyl
- or Ra O--CO-- group, where Ra is hydrogen or C1-4 alkyl
This creates two major commercial implementation routes:
- tetrazole analogs (covered)
- carboxylate/ester-like variants depending on Ra (also covered as defined)
How do Claims 4 to 6 narrow to a specific chemical “species cluster”?
Claim 4 enumerates six specific compounds:
-
Carboxylic acid with:
- 2-n-propyl, 4-methyl
- benzimidazole substituted at 1-methyl
- unsubstituted benzimidazole benzene ring (no fluorine on benzimidazole phenyl nucleus)
-
Tetrazolyl analog with the same benzimidazole substitution pattern as (1)
-
Carboxylic acid with:
- benzimidazole benzene ring substituted by fluorine (1-methyl-5-fluoro benzimidazole)
-
Tetrazolyl analog with:
- 2-n-butyl instead of n-propyl
- benzimidazole benzene ring unsubstituted (no fluorine)
-
Carboxylic acid with:
- 1-methyl-6-fluoro benzimidazole (fluorine position variant)
- 2-n-propyl, 4-methyl
-
Carboxylic acid with:
- benzimidazole benzene ring 5-fluoro
- and R3 = 2-ethyl (2-ethyl at the relevant position in the named structure)
What is covered beyond the enumerated list?
Even though Claim 4 lists six, Claim 1 still covers additional members, because it is not restricted to only the enumerated R1/R2/R3/R4 combinations. Claims 5 and 6 then provide two single-species anchors that may be important for enforcement if infringement evidence is most persuasive against those exact structures.
What is the US patent “landscape” risk for this patent based on the claim subject matter?
Key landscape drivers
Without litigation history or family/patent-citation mapping, landscape analysis must be anchored to claim scope mechanics. In that framework, the biggest landscape pressures for US 5,591,762 are:
-
Heteroaryl benzimidazole substitution space
- Claim 1’s limitations on benzimidazole identity and permitted substitutions create a finite boundary. Competitors can pursue nearby space by changing:
- the benzimidazole substitution pattern outside F/methyl/CF3,
- or the benzimidazole substitution positions beyond allowed “1-position optional alkyl/cycloalkyl” and benzene-ring substitution types.
- This typically attracts follow-on filings from teams seeking to avoid a specific Markush set.
-
R4 duality: tetrazole vs Ra O--CO
- If a competitor uses a different tetrazole attachment form or a different carboxyl derivative logic not fitting Ra O--CO with Ra in H or C1-4 alkyl, it can evade Claim 1.
- If the competitor uses other bioisosteres in the same slot, it can reduce literal infringement likelihood.
-
Biphenyl substitution pattern
- The claims are tightly tied to a biphenyl system bearing the benzimidazole-methyl linkage and the carboxylic acid or tetrazolyl functionality at the “2-” position as written in the enumerated species.
- Competitors shifting the position of the pharmacophore on the biphenyl ring are likely to fall outside the defined formula.
-
Method and composition claims are compound-dependent
- Claims 7 and 8 do not broaden coverage beyond the compound set; they are derivative. A claim design-around that avoids the compound claims typically neutralizes the downstream composition and use claims.
Competitive freedom inside the genus
The genus still has meaningful internal flexibility:
- R1 allows multiple classes (C1-4 alkyl, C3-7 cycloalkyl, CF3)
- R2 allows different 1-substituents (C1-6 alkyl or C3-7 cycloalkyl) plus benzene-ring F/methyl/CF3
- R3 spans C1-5 alkyl plus cyclopropyl
- R4 includes both tetrazole and defined Ra O--CO variants
This increases the risk that many “neighbor” compounds are also covered, unless competitors stay strictly within the forbidden substitution sets.
Litigation-style enforceability posture implied by claims
- Broadest claim is Claim 1, but it carries the burden of showing that accused compounds fit the full variable constraints.
- Claims 5 and 6 give enforcement leverage if accused products match those exact structures.
- Claim 4 provides multiple enumerated anchors that can reduce proof complexity against a set of candidate products, even if exact match is not one of Claims 5 or 6.
Where are the most likely “design-around” seams in this claim set?
-
Benzimidazole benzene-ring substitution class
- Allowed: F, methyl, trifluoromethyl
- Design-around seam: substituents outside these classes (or absent where required by the formula reading).
-
R2 identity and substitution positioning
- Allowed: benzimidazol-2-yl with optional 1-position substitution limited to C1-6 alkyl or C3-7 cycloalkyl.
- Design-around seam: changing the linkage to a different benzimidazole position or altering the heterocycle class.
-
R4 form
- Allowed: 1H-tetrazolyl or Ra O--CO with Ra restricted to H or C1-4 alkyl.
- Design-around seam: different isosteric rings or acyl/alkoxy structures outside the Ra definition.
-
R1 class boundaries
- Allowed: C1-4 alkyl, C3-7 cycloalkyl, CF3.
- Design-around seam: substituents outside these ranges (for example, larger alkyls, different aryls, or substituted aromatics).
How do the composition and method claims expand commercial relevance?
Claim 7: composition coverage
Claim 7 covers pharmaceutical compositions containing therapeutically effective amounts of compounds in claims 1 to 6.
Infringement relevance:
- A product that uses any covered compound in a formulation fits, regardless of which specific salt form is used, as long as it falls under “pharmaceutically acceptable salts.”
Claim 8: hypertension indication
Claim 8 covers administering to a mammalian host suffering from hypertension an antihypertensive amount of a covered compound.
Infringement relevance:
- Product labeling and prescribing context can become pivotal. Even if the same compound is used for other indications, Claim 8 targets hypertension use specifically.
Tabular scope map (what the patent covers vs what it implicitly excludes)
| Claim element |
Included (literal per text) |
Built-in exclusion pressure |
| R1 (4-position) |
C1-4 alkyl, C3-7 cycloalkyl, CF3 |
Alkyl outside C1-4, aryl substituents, other halogens not specified for R1 |
| R2 core |
benzimidazol-2-yl |
Other heteroaryl cores or benzimidazole not in 2-yl form |
| R2 1-position substituent |
optional C1-6 alkyl or C3-7 cycloalkyl |
Other substituent types at 1-position not in allowed ranges |
| Benzimidazole benzene-ring substituent |
F, methyl, or CF3 |
Other substituents (other halogens, nitro, cyano, etc.) |
| R3 |
C1-5 alkyl or cyclopropyl |
Larger alkyls or different ring types |
| R4 |
1H-tetrazolyl or Ra O--CO group |
Other carboxy derivatives not matching Ra O--CO with Ra in H or C1-4 alkyl |
| Downstream claims |
Composition (Claim 7) and hypertension method (Claim 8) |
No independent broader coverage beyond compound claims |
Key Takeaways
- US 5,591,762 claim scope is compound-centric and defined by strict substituent constraints on R1-R4 in formula I.
- Claims 1 to 3 establish a structured genus with bounded substituent classes on the benzimidazole and biphenyl framework.
- Claims 4 to 6 provide enumerated species anchors (carboxylic acid and tetrazolyl forms; fluorinated benzimidazole variants included).
- Composition (Claim 7) and hypertension method (Claim 8) are dependent on practicing the covered compounds; design-arounds that remove literal fit to Claims 1-6 largely neutralize downstream coverage.
- Most credible design-around seams are the benzimidazole benzene-ring substituent set, R2 substitution pattern/positioning, and the R4 functional class limits.
FAQs
1) What is the broadest claim in US 5,591,762?
Claim 1 is the broadest, covering formula I compounds with R1-R4 defined substituent classes and salts.
2) Does the patent protect both carboxylic acid and tetrazolyl analogs?
Yes. Claim 1 defines R4 as 1H-tetrazolyl or Ra O--CO-- (with Ra in H or C1-4 alkyl), and Claim 4 explicitly lists both biphenyl-2-carboxylic acid and 2-(1H-tetrazol-5-yl)-biphenyl members.
3) Which claim limits the positional placement of R2?
Claim 2 requires R2 is in the 6-position (per the formula framework), narrowing Claim 1.
4) Are specific compounds explicitly claimed in addition to the genus?
Yes. Claim 4 enumerates six specific compounds, and Claims 5 and 6 single out two of them.
5) Do the composition and method claims broaden beyond the compound claims?
No. Claims 7 and 8 cover compositions and hypertension treatment only using compounds covered by claims 1 through 6.
References
[1] United States Patent 5,591,762, claims 1-8 (as provided in the prompt).
